8-K: Baxter International Reports Mixed Q4 and Full-Year 2023 Results, Provides 2024 Outlook

Baxter International's fourth-quarter results showed a 4% sales increase, while full-year results included a net loss from continuing operations, alongside progress on strategic initiatives.

Summary

• Baxter International reported a 4% increase in fourth-quarter sales from continuing operations, reaching $3.89 billion, with a 3% increase on a constant currency basis.
• The company's U.S. GAAP diluted earnings per share (EPS) from continuing operations for the fourth quarter was $0.14, and adjusted diluted EPS was $0.88.
• Full-year sales from continuing operations totaled $14.81 billion, a 2% increase on a reported basis and 3% on a constant currency basis.
• The full-year U.S. GAAP diluted EPS from continuing operations was a loss of ($0.15), while adjusted diluted EPS was $2.60.
• Baxter's net income attributable to Baxter stockholders for the full year was $2.66 billion, or $5.25 per diluted share, which includes a gain from the divestiture of the BioPharma Solutions business.
• The company generated $1.70 billion in operating cash flow from continuing operations and $1.01 billion in free cash flow for the full year.
• Baxter is progressing with the proposed separation of its Kidney Care segment into a standalone company named Vantive.
• For full-year 2024, Baxter expects sales growth of approximately 2% on both a reported and constant currency basis, with adjusted earnings of $2.85 to $2.95 per diluted share.
• For the first quarter of 2024, the company anticipates sales growth of approximately 1% on a reported basis and 1% to 2% on a constant currency basis, with adjusted earnings of $0.59 to $0.62 per diluted share.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a GAAP loss for the full year, the adjusted results and strategic initiatives show progress. The forward-looking guidance is also positive, but there are still risks and challenges ahead.

Positives

• Baxter's fourth-quarter sales exceeded previous guidance, driven by strong performance in Medical Products and Therapies, Kidney Care, and Pharmaceuticals segments.
• The company made significant progress in 2023 with its capital allocation priorities, using proceeds from the BPS sale for debt repayment.
• The launch of new products and technologies across various segments demonstrates innovation and growth potential.
• The Sharesource platform's impact on reducing PD technique failure highlights the company's commitment to improving patient outcomes.
• Baxter's commitment to corporate responsibility is evident through its inclusion in the Dow Jones Sustainability Index and other recognitions.

Negatives

• The full-year U.S. GAAP diluted EPS from continuing operations resulted in a loss of ($0.15).
• Kidney Care sales declined in the fourth quarter due to difficult comparisons to the prior year and lower sales in select international markets.
• The company's full-year operating income was significantly impacted by goodwill impairments, resulting in a loss of $2.243 billion.
• The company's free cash flow from continuing operations was $1.01 billion, which is lower than the operating cash flow of $1.70 billion due to capital expenditures of $692 million.

Risks

• The company's ability to execute and complete strategic initiatives, including the proposed separation of the Kidney Care business, is subject to various conditions and uncertainties.
• Failure to accurately forecast or achieve shortand long-term financial goals could impact the company's liquidity.
• Global economic conditions, including inflation, interest rates, and geopolitical conflicts, could affect the company's operations.
• Product development risks, regulatory approvals, and product quality issues could lead to recalls, delays, or declining sales.
• Cybersecurity breaches and failures in information technology systems pose a risk to the company's operations and data.
• The company faces risks related to the continuity, availability, and pricing of raw materials and component parts.
• Changes in legislation, regulation, and governmental pressures could impact the company's compliance costs and potential penalties.
• The company is exposed to competitive pressures, including generic competition and disruptive technologies.

Future Outlook

Baxter expects full-year 2024 sales growth of approximately 2% on both a reported and constant currency basis, with adjusted earnings of $2.85 to $2.95 per diluted share. For the first quarter of 2024, the company anticipates sales growth of approximately 1% on a reported basis and 1% to 2% on a constant currency basis, with adjusted earnings of $0.59 to $0.62 per diluted share.

Management Comments

• Baxters performance in 2023 reflects our building momentum as we executed upon several strategic initiatives designed to enhance our future performance, including the implementation of a new operating model, the sale of our BioPharma Solutions business and steady progress on the proposed separation of our Kidney Care segment, said Jos (Joe) E. Almeida, chair, president and chief executive officer.
• Consistent with our focus on advancing Baxters transformation journey and creating value for our stakeholders, we made significant progress in 2023 in line with our capital allocation priorities, said Joel Grade, executive vice president and chief financial officer.
• Most notably, net after-tax proceeds from the sale of our BioPharma Solutions business were allocated towards debt repayment. During 2024, we will remain focused on deleveraging while also significantly enhancing our focus on cash flow generation.

Industry Context

This announcement reflects the ongoing trends in the medical technology industry, including strategic divestitures, focus on core business segments, and the development of innovative healthcare solutions. The proposed separation of the Kidney Care segment is in line with the industry trend of companies streamlining their operations to focus on specific areas of expertise. The launch of new digital health solutions and medical devices also aligns with the industry's push towards technological advancements.

Comparison to Industry Standards

• Baxter's 2% full-year sales growth is moderate compared to some high-growth medtech companies, but it is in line with the performance of established players in the medical device sector.
• Companies like Medtronic and Abbott have reported similar growth rates in certain segments, while others have seen higher growth due to specific product launches or market conditions.
• The divestiture of the BioPharma Solutions business is similar to moves by other large medtech companies to focus on core competencies and improve profitability.
• The proposed separation of the Kidney Care segment mirrors the trend of companies spinning off divisions to unlock value and allow for more focused management and investment.
• Baxter's adjusted EPS of $2.60 for the full year is within the range of other large medical device companies, but the GAAP loss highlights the impact of special items and restructuring costs.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results, strategic initiatives, and the proposed separation of the Kidney Care segment.
• Employees will be affected by the ongoing business transformation and the creation of the new Vantive company.
• Customers will benefit from the launch of new products and technologies.
• Patients will benefit from improved healthcare solutions and therapies.
• Suppliers will be impacted by the company's focus on streamlining its operations.

Next Steps

• Baxter will continue to advance its business transformation and prepare for the proposed separation of its Kidney Care segment.
• The company plans to launch the Progressa+ ICU bed in additional global markets in 2024.
• Baxter will remain focused on deleveraging and enhancing cash flow generation in 2024.
• The company will continue to report against the TCFD framework in its annual Corporate Responsibility Report.

Key Dates

Keywords

Baxter International, Medtech, Financial Results, Earnings, Sales Growth, Kidney Care, Vantive, BioPharma Solutions, Medical Devices, Pharmaceuticals, Healthcare Systems, Operating Income, EPS, Free Cash Flow, Strategic Initiatives